Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe

Hartwig, Susanne; Guily, Jean Lacau St; Dominiak-Felden, Geraldine; Alemany, Laia; Sanjosé, Sílvia de

doi:10.1186/s13027-017-0129-6

Cited by 94 publications

(70 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…About 80% of these cases occur in women and 20% in men. 13 Cervical cancer represents the highest burden (31,130 cases), followed by head and neck cancer (1,396 cases in women, 5,834 cases in men), anal cancer (3,834 in women and 2,303 cases in men), vulvar cancer (1,466 cases), vaginal cancer (1,360 cases), and penile cancer (1,113 cases).…”

Section: Hpv-related Diseasesmentioning

confidence: 99%

Jabs for the Boys

Baker¹,

Prue²,

Rae³

et al. 2019

International Journal of Men's Social and Community Health

View full text Add to dashboard Cite

The human papillomavirus (HPV) can cause a range of cancers as well as genital warts and recurrent respiratory papillomatosis in men and women. Most cases can be prevented by vaccination in adolescence. Many countries vaccinate girls and an increasing number, although still a minority, vaccinate both boys and girls. The case for vaccinating boys is based on arguments of public health, equity, ethics and cost-effectiveness. The selective vaccination of females does not protect males sufficiently and provides no protection at all for men who have sex with men. In the United Kingdom (UK), the government’s vaccination advisory committee (Joint Committee on Vaccination and Immunisation [JCVI]) began to consider whether boys should be vaccinated as well as girls in 2013 and made clear in draft statements that it considered this not to be cost-effective. A campaign group, HPV Action, was established to advocate gender-neutral vaccination. This group became a coalition of over 50 organisations and used evidence-based arguments, political advocacy and media campaigning to make its case. One of its members initiated legal action against the government on the grounds of sex discrimination. In July 2018, the government agreed that boys in the UK should be vaccinated. The lessons for other campaigns in the men’s and public health fields include: be prepared for the long haul, focus on clear and specific goals, build alliances, align the objectives with existing policies, make a financial case for a change of policy, and use all legitimate means to exert pressure.

show abstract

Section: Hpv-related Diseasesmentioning

confidence: 99%

Jabs for the Boys

Baker¹,

Prue²,

Rae³

et al. 2019

International Journal of Men's Social and Community Health

View full text Add to dashboard Cite

show abstract

“…Low-risk genotypes 6 and 11 mainly cause cervical, vulvar and vaginal low-grade lesions, and are responsible for 90% of the anogenital warts or condyloma acuminatum. [1][2][3] Vaccination represents one of the most cost-effective public health measures. The development of the prophylactic vaccine against HPV, with the aim of preventing the initial infection and subsequent neoplastic transformation, has generated some controversy.…”

Section: Introductionmentioning

confidence: 99%

“…The nonavalent vaccine in the two-dose scheme replaced the quadrivalent vaccine in January 2017, and has been covering girls aged 10 years. [2][3][4][5][6] Vaccination in males is recommended by several national and international scientific societies, and its introduction into the immunisation schedule is currently being discussed in Portugal.…”

Section: Introductionmentioning

confidence: 99%

Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review

Medeiros¹,

Vaz²,

Rebelo³

et al. 2020

Acta Med Port

View full text Add to dashboard Cite

Introduction: Human papillomavirus is responsible for almost all cases of cervical cancer, an important portion of anogenital and oropharyngeal invasive and preinvasive lesions, as well as genital warts (condyloma acuminatum) and recurrent respiratory papillomatosis. Currently, three prophylactic vaccines against high-risk Human papillomavirus are commercialized in many countries worldwide. Methods: To this non-systematic review the authors searched in MEDLINE/PubMed for systematic reviews, meta-analysis and randomized controlled trials, published in the last six years, using the terms “HPV”, “non-cervical cancer” and “vaccine”. Non-cervical cancers caused by human papillomavirus are less common lesions. However, its incidence has been increasing, while cervical cancer has declined, due mainly to highly effective screening programs. There are no formal screening programs for non-cervical cancers, so universal vaccination could have an important impact. The preventive effect of the vaccine is mainly studied and established in relation to cervical cancer, although it has also been demonstrated in the development of vulvar and vaginal lesions. To date, the efficacy in preventing anal and oropharyngeal diseases related with human papillomavirus is uncertain due to scarce supporting data and low vaccination coverage in men. The prevalence of injuries and subsequent absolute benefit of vaccination is lower in men, but it provides an additional benefit to the herd immunity achieved with the vaccination of women.Conclusion: The total fraction of malignant and pre-malignant lesions attributed to Human papillomavirus genotypes contained in the nonavalent vaccine is significant in both women and men, which turns this vaccine into a great asset in terms of Public Health.

show abstract

“…Infection with one type of HPV does not prevent infection with a different type. 5% to 30% out of mucosal HPV infections are caused by multiple strains of the virus [1][2][3] .…”

Section: Introductionmentioning

confidence: 99%

“…According to the Centers for Disease Control and Prevention (CDC), anogenital HPV is the most common sexually-tra nsmitted infection, 8 in 10 sexually active people will be infected in their lifetime with at least one strain of HPV 1,2 . The prevalence of the detectable HPV infection in European women from the general population is estimated to be 14% and it reaches a peak in the age groups represented by adolescents and women in their early 20s 3,4 .…”

Section: Introductionmentioning

confidence: 99%

Clinical manifestations and burden of HPV infection – prevention and therapeutic possibilities

Cioti¹,

Bucharest²,

Stănescu³

et al. 2019

Arch Balk Med Union

View full text Add to dashboard Cite

Manifestations cliniques et fardeau d'une infection à HPV-prévention et possibilités thérapeutiques Le virus du papillome humain (VPH) est le virus responsable de la plus commune et répandue infection sexuellement transmissible. La plupart des personnes sexuellement actives contracteront au moins un type de VPH au cours de leur vie et certaines pourront être infectées à plusieurs reprises. Dans la plupart des cas, l'infection à HPV est transitoire et asymptomatique, mais si l'infection persiste, elle peut provoquer des maladies bénignes, des lésions précancéreuses et des tumeurs malignes à divers endroits. Les types de HPV à faible risque peuvent produire des lésions prolifératives dans la peau ou les muqueuses, alors que les types à haut risque possèdent un potentiel cancérogène. Cet article passe en revue les dernières données de la littérature concernant les manifestations cliniques des

show abstract

Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe

Cited by 94 publications

References 22 publications

Jabs for the Boys

Jabs for the Boys

Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review

Clinical manifestations and burden of HPV infection – prevention and therapeutic possibilities

Contact Info

Product

Resources

About